Naratriptan Morningside Healthcare (Naratriptan)

Naratriptan works by selectively stimulating serotonin 5‑HT1B and 5‑HT1D receptors in the brain. This action causes constriction of dilated cranial blood vessels and blocks the release of inflammatory neuropeptides from trigeminal nerves, thereby reducing migraine pain and associated symptoms.

The appropriate dose of naratriptan is determined by the prescribing clinician based on the patient’s medical history, severity of migraine, and other individual factors. Patients should follow the prescriber’s instructions and not alter the dose without medical advice.

Safety data for naratriptan in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using this medication.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Naratriptan belongs to the triptan class, which is generally more specific for migraine relief than non‑specific analgesics such as NSAIDs. Compared with other triptans, naratriptan has a longer half‑life, allowing a single dose to provide sustained relief for many patients.

Naratriptan tablets should be stored at room temperature, below 25 °C, in the original container. Keep the product away from moisture, direct sunlight, and excessive heat to maintain its stability and potency.

Naratriptan is taken orally as a tablet. The tablet should be swallowed whole with a glass of water, preferably as soon as migraine symptoms begin. Patients should not crush, chew, or split the tablet unless specifically instructed by a healthcare professional.

Serious risks include cardiovascular events such as chest pain or myocardial infarction, especially in patients with underlying heart disease, and serotonin syndrome when combined with other serotonergic agents. Any sudden or severe symptoms should prompt immediate medical attention.

Naratriptan is contraindicated in individuals with uncontrolled hypertension, a history of ischemic heart disease, severe hepatic impairment, or known hypersensitivity to the drug. It should also be avoided in patients currently taking MAO inhibitors or ergot alkaloids.